Erweitertes Portfoli
Erweitertes Portfolio für Biopharma und Lebensmittelsicherheit: QIAGEN bringt neue digitale PCR-Kits und aktualisierte Software für QIAcuity auf den Markt
November 09, 2023 16:05 ET | QIAGEN N.V.
VENLO, Niederlande, Nov. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Einführung von drei neuen Kits und ein wichtiges Software-Update für seine...
Pipeline ...
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results
February 27, 2023 16:30 ET | Recursion Pharmaceuticals
Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readoutsDelivered against core elements of our Roche-Genentech...
Picture1 (1).jpg
Kymanox Acquires EU based Anteris Medical and Anteris Helvetia
February 02, 2023 13:57 ET | Kymanox Corporation
MORRISVILLE, N.C. and HOLZKIRCHEN, Germany and KÜSSNACHT A.R., Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Kymanox Corporation (“Kymanox”), a professional services company exclusively...
Ruzurgi product image
Médunik Canada obtient un nouvel avis de conformité de Santé Canada pour Ruzurgi® (amifampridine) suite à une décision favorable de la Cour d'appel fédérale du Canada
January 17, 2023 07:00 ET | Médunik Canada inc.
BLAINVILLE, Québec, 17 janv. 2023 (GLOBE NEWSWIRE) -- Médunik Canada inc. (« Médunik »), une entreprise vouée à l'amélioration de la santé et de la qualité de vie des Canadiens atteints de...
Ruzurgi product image
Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi® (amifampridine) following a favourable Canadian Federal Court of Appeal ruling
January 17, 2023 07:00 ET | Medunik Canada Inc.
BLAINVILLE, Quebec, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Medunik Canada Inc. (“Medunik”), a company dedicated to improving the health and quality of life of Canadians with rare diseases by bringing...